CrossBridge Bio - About the company
CrossBridge Bio is an acquired company based in Houston (United States), founded in 2023 by Michael Jason Torres, Kyoji Tsuchikama and Zhiqiang An. It operates as a Developer of Antibody-Drug Conjugate therapeutics. CrossBridge Bio has raised $10M in funding from investors like Crescent Enterprises, CE Ventures and TMC Venture Fund, with last known valuation of $*****. The company has 3446 active competitors, including 1139 funded and 791 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Kite Pharma.
Company Details
Developer of Antibody-Drug Conjugate therapeutics. It offer therapeutics based on stable dual-linker payload technology which include a lead candidate CB-120 for cancer treatment.
- Website
- crossbridgebio.com
- Social
Key Metrics
Founded Year
2023
Location
Houston, United States
Stage
Acquired
Total Funding
$10M in 1 round
Latest Funding Round
Last Known Valuation
$***** as on Jun 05, 2026
Investors
Ranked
503rd among 3446 active competitors
Employee Count
2 as on Sep 30, 2026
Exit Details
Acquired by Lilly (Apr 14, 2026)
CrossBridge Bio's acquisition details
CrossBridge Bio got acquired by Lilly on Apr 14, 2026.
Click here to take a look at CrossBridge Bio's acquisition in detail
Sign up to download CrossBridge Bio's company profile
CrossBridge Bio's funding and investors
CrossBridge Bio has raised a total funding of $10M over 1 round. Its latest funding round was a Seed round on Nov 04, 2024 for $*****. 6 investors participated in its latest round. CrossBridge Bio has 6 institutional investors.
Here is the list of recent funding rounds of CrossBridge Bio:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Nov 04, 2024 | 8509495 | Seed | 9844292 | 3401053 | 6628036 | 3334565 |
Access funding benchmarks and valuations. Sign up today!View details of CrossBridge Bio's funding rounds and investors
CrossBridge Bio's founders and board of directors
Founder? Claim ProfileHere are the details of CrossBridge Bio's key team members:
- Michael Jason Torres: Co-Founder & Chief Executive Officer of CrossBridge Bio. Contact Info: 1 email address
- Kyoji Tsuchikama: Co-Founder of CrossBridge Bio. Contact Info: 1 email address
- Zhiqiang An: Co-Founder of CrossBridge Bio. Contact Info: 1 email address
View details of CrossBridge Bio's Founder profiles and Board Members
CrossBridge Bio's employee count trend
CrossBridge Bio has 2 employees as of Sep 26. Here is CrossBridge Bio's employee count trend over the years:
Uncover CrossBridge Bio's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
CrossBridge Bio's Competitors and alternates
Top competitors of CrossBridge Bio include Jazz Pharmaceuticals, BeiGene and Kite Pharma. Here is the list of Top 10 competitors of CrossBridge Bio, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 82/100 | |
2nd |  BeiGene 2010, Cambridge (United States), Public | Developer of targeted and immune-oncology drugs against cancer | $172M | 77/100 | |
3rd | Kite Pharma 2009, Los Angeles (United States), Acquired | Developer of cancer immunotherapy products using genetic engineering | $97.7M | 76/100 | |
4th |  Attovia 2023, Fremont (United States), Public | Developer of antibody-based therapeutics for immune-mediated diseases and oncology | $255M | 72/100 | |
5th |  Tango Therapeutics 2017, Cambridge (United States), Public | Developer of drugs for the treatment of cancer | $165M | 72/100 | |
6th |  Elicio 2012, Cambridge (United States), Public | Developer of vaccines for treating cancer | $47.4M | 72/100 | |
7th | Developer of T-cell therapies for the treatment of cancer | $49.8M | 71/100 | ||
8th | Developer of immunotherapeutics for the treatment of cancer and other diseases | $861M | 71/100 | ||
9th | _1545299782322.png?devicePixelRatio=2&height=30&width=30){kind=logo} Erasca 2018, San Diego (United States), Public | Developer of small molecule based therapeutics for cancer | $300M | 71/100 | |
10th |  Strand Therapeutics 2017, Cambridge (United States), Series B | Provider of platform to deliver mRNA therapeutics for multi functional treatments | $256M | 71/100 | |
503rd | CrossBridge Bio 2023, Houston (United States), Acquired | Developer of Antibody-Drug Conjugate therapeutics | $10M | 52/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on CrossBridge Bio's competitors? Click here to see the top ones
CrossBridge Bio's Investments and acquisitions
CrossBridge Bio has made no investments or acquisitions yet.
Reports related to CrossBridge Bio
Here is the latest report on CrossBridge Bio's sector:
News related to CrossBridge Bio
Media has covered CrossBridge Bio for a total of 6 events in the last 1 year, 2 of them have been about company updates.
•
Linden Lake Labs Applauds Acquisition of Portfolio Company CrossBridge Bio by Eli Lilly and CompanyBusiness Wire•Apr 14, 2026•Lindenlakelabs, Lilly, CrossBridge Bio, Cooley and 3 others
•
Eli Lilly to buy Centessa Pharmaceuticals for up to $7.8 billionMoneycontrol•Mar 31, 2026•Centessa Pharmaceuticals, Lilly, Goodwin, CrossBridge Bio
•
CrossBridge Bio Awarded $15 Million CPRIT Grant to Advance CBB-120, Its Lead Dual-Payload ADC Targeting TROP-2, Into the Clinichttps://www.intelligence360.news/•Dec 18, 2025•CrossBridge Bio
•
CrossBridge Bio Awarded $15 Million CPRIT Grant to Advance CBB-120, Its Lead Dual-Payload ADC Targeting TROP-2, Into the ClinicBusiness Wire•Nov 20, 2025•CrossBridge Bio
•
CrossBridge Bio Wins “Best Drug Developer” at 2025 World ADC AwardsBusiness Wire•Nov 07, 2025•CrossBridge Bio
•
Everfuel: First hydrogen delivery to Crossbridge Energy successfully completedCision•Feb 28, 2025•Everfuel, CrossBridge Bio
•
CrossBridge Bio Secures $10 Million Financing to Advance the Development of Next-Generation Dual-Payload ADC Therapieshttps://www.intelligence360.news/•Nov 12, 2024•CrossBridge Bio, Linden Lake Venture Capital, TMC Venture Fund, Crescent Enterprises and 1 other
•
CrossBridge Bio Secures $10 Million Financing to Advance the Development of Next-Generation Dual-Payload ADC TherapiesBakersfield•Nov 04, 2024•CrossBridge Bio, TMC Venture Fund, CE Venture Capital, Portal Innovations and 3 others
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about CrossBridge Bio
Explore our recently published companies
- Simply Superior - Marquette based, 2014 founded, Unfunded company
- Sinan Guler - Turkey based, Unfunded company
- Sirkhet - Izmir based, 2017 founded, Unfunded company
- Sinapsis - Mexico based, Unfunded company
- Sirin Thaimassage - Germany based, Unfunded company
- Sipiteno - Larnaca based, 2009 founded, Unfunded company
